Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | STAT5B | P51692 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413673 | 0.77 | CNR2 (0.45) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL28339490 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL4409003 | 0.77 | CNR2 (0.49) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL4407850 | 0.77 | CNR2 (0.45) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL4407041 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL9643255 | 0.77 | MGLL (0.59) | ALDH1A1MGLLFAAHTRPV1DAGLA | |
| SCHEMBL4406847 | 0.76 | ALDH1A1 (0.59) | ALDH1A1CNR2STAT5BMEN1KMT2A | |
| SCHEMBL4405904 | 0.76 | HSD11B1 (0.59) | ALDH1A1HSD11B1MEN1KMT2APOLB | |
| SCHEMBL2092704 | 0.74 | CNR2 (0.54) | ALDH1A1MGLLFAAHCNR2TRPV1 | |
| SCHEMBL28099662 | 0.74 | CNR2 (0.54) | ALDH1A1MGLLFAAHCNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946686-A | Composition for selectively etching aluminum oxide | 安集微电子科技（上海）股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-111039977-B | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | FUTURESYNTHESIS SPÓLKA Z O.O. (PL) | 2022-01-27 | — | — | US | claimed |
| EP-3891225-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | Futuresynthesis Spólka z o.o. (PL) | 2021-10-13 | — | — | EP | claimed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | claimed |
| WO-2020117079-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | FUTURESYNTHESIS SPÓLKA Z O.O. (PL) | 2020-06-11 | — | — | WO | claimed |
| CN-111039977-A | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | claimed |
| EP-2053054-B1 | METHOD FOR INTRODUCING NUCLEIC-ACID-PROTECTING GROUP | NIPPON SHINYAKU CO LTD (JP) | 2014-12-17 | — | — | EP | claimed |
| EP-1795536-B1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | NIPPON SHINYAKU CO LTD (JP) | 2012-05-02 | — | — | EP | claimed |
| US-8158774-B2 | Method for introducing a nucleic-acid protecting group | NIPPON SHINYAKU CO., LTD. (JP) | 2012-04-17 | — | — | US | claimed |
| EP-1848730-B1 | PHOSPHORAMIDITE ACTIVATOR FOR OLIGONUCLEOTIDE SYNTHESE | HONEYWELL INT INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NIPPON SHINYAKU CO., LTD. (JP) | 2009-12-17 | — | — | US | claimed |
| US-20090286970-A1 | METHOD FOR INTRODUCING A NUCLEIC-ACID PROTECTING GROUP | NIPPON SHINYAKU CO., LTD. (JP) | 2009-11-19 | — | — | US | claimed |
| EP-2053054-A1 | METHOD FOR INTRODUCING NUCLEIC-ACID-PROTECTING GROUP | Nippon Shinyaku Co., Ltd. (JP) | 2009-04-29 | — | — | EP | claimed |
| EP-1995252-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | claimed |
| US-7339052-B2 | Phosphoramidite activator for oligonucleotide synthesis | HONEYWELL INTERNATIONAL INC. (US) | 2008-03-04 | — | — | US | claimed |
| EP-1848730-A1 | PHOSPHORAMIDUTE ACTIVATOR FOR OLIGONUCLEOTIDE SYNTHESIS | Honeywell International, Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006086186-A1 | PHOSPHORAMIDUTE ACTIVATOR FOR OLIGONUCLEOTIDE SYNTHESIS | HONEYWELL INTERNATIONAL INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060178509-A1 | Phosphoramidite activator for oligonucleotide synthesis | SOLSTICE ADVANCED MATERIALS US, INC. | 2006-08-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NSUN2, RNASEH1, RNASE1 | ALDH1A1 1799/4885MGLL 2670/4885FAAH 3584/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | ALDH1A1 1956/4885MGLL 4315/4885FAAH 2588/4885 |
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | DUT, NOP2, NUDT1 | ALDH1A1 509/4885MGLL 2631/4885FAAH 1541/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | ALDH1A1 1416/4885MGLL 4133/4885FAAH 1914/4885 |
| US-20090286970-A1 | METHOD FOR INTRODUCING A NUCLEIC-ACID PROTECTING GROUP | RNASEH1, SNRPB2, SNRPA1 | ALDH1A1 591/4885MGLL 4415/4885FAAH 3200/4885 |
| US-20060178509-A1 | Phosphoramidite activator for oligonucleotide synthesis | RNGTT, TYMP, DUT | ALDH1A1 4051/4885MGLL 4026/4885FAAH 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.